For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...

Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...

The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL ...

The global burden of chronic lymphocytic leukemia (CLL) has decreased over the past 30 years, according to a new analysis. However, the authors of the new report published in Cancer Control noted that ...

Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer Chronic lymphocytic leukemia (CLL) has unique epidemiologic, biologic, and clinical ...